Datasheet

erbB-2 Antibody
CATALOG NUMBER: 5153

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, IP, WB
APPLICATIONS:erbB-2 antibody can be used for detection of erbB-2 by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 2.5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1464 - Rat Liver Tissue Lysate
 2) Cat. No. 10-201 - Human Liver Tissue Slide
IMMUNOGEN:erbB-2 antibody was raised against a 19 amino acid synthetic peptide near the carboxy terminus of human erbB-2.

The immunogen is located within the last 50 amino acids of erbB-2.
HOST SPECIES:Chicken

Properties

PURIFICATION:erbB-2 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:erbB-2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:erbB-2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgY
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:erbB-2 Antibody: NEU, NGL, HER2, TKR1, CD340, HER-2, MLN 19, HER-2/neu, MLN19, NEU, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein
ACCESSION NO.:NP_004439
PROTEIN GI NO.:54792096
OFFICIAL SYMBOL:ERBB2
GENE ID:2064

Background

BACKGROUND:erbB-2 Antibody: The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, PI3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.
REFERENCES: 1) Baselga J and Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nature Rev.2009; 9:463-475.
2) Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science1987; 235:177-82.
3) Vermeij J, Teugels E, Bourgain C, et al. Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers. BMC Cancer2008; 8:3.
4) Marmor MD, Skaria KB, and Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int. J. Rad. Oncol. Biol. Phys.2004; 58:903-13.

For Research Use Only